ARS Pharmaceuticals, Inc. SPRY Accounts payable and other current liabilities (Note 11)
Accounts payable and other current liabilities (Note 11) at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s accounts payable and other current liabilities (note 11).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s accounts payable and other current liabilities (note 11)?
- ARS Pharmaceuticals, Inc. (SPRY) reported accounts payable and other current liabilities (note 11) of $48.26M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s accounts payable and other current liabilities (note 11) changed year-over-year?
- ARS Pharmaceuticals, Inc.'s accounts payable and other current liabilities (note 11) increased by 78.7% year-over-year, from $27.01M to $48.26M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s accounts payable and other current liabilities (note 11)?
- Over 4 years (2021 to 2025), ARS Pharmaceuticals, Inc.'s accounts payable and other current liabilities (note 11) has grown at a 86.9% compound annual growth rate (CAGR), from $3.11M to $37.95M.